Form 8-K · Current Report · Filed 2026-04-01
Natera Appoints New Director Eric Rubin
Natera, Inc. announced the appointment of Dr. Eric Rubin as a new member of its Board of Directors, effective March 26, 2026. The Board also increased its size from ten to eleven members. Dr. Rubin will serve as a Class I director with an initial term expiring at the 2028 annual meeting of stockholders. He will receive compensation consistent with the Company's other non-employee directors and will be entitled to an initial equity award that will vest over three years. There are no family relationships between Dr. Rubin and any of the Company's directors or executive officers.
- Filer
- Natera Inc. NTRA · NASDAQ
- Filed
- Accession
- 0001104659-26-038519
- CIK
- 0001604821
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$199.99
Next session
+4.0%
Since filing
+33.9%
Latest close
$267.76
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from NTRA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, NTRA insiders reported 20 Form 4 transactions — net selling of $2.7M.
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Never miss another NTRA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.